About Us

About Tantti

     Tantti Laboratory Inc. (“Tantti”) was founded in 2014 by eight distinguished professors in Taiwan with expertise in Chemical and Materials Engineering. Since its inception, the company has developed two platform technologies (Tantti® Monolith and Tantti® BioScaffolds) which use in-mold polymerization and microfluidics to create highly ordered micro- and nano-porous biomaterials.


▪Tantti® DuloCore™ represents a breakthrough in liquid chromatographic technology used in the separation and purification of large biomolecules, including DNA plasmids, mRNA, viral vectors, viruses and exosomes. Its applications target downstream process (DSP) of biopharma products in advanced therapies and vaccines.


▪Tantti® BioScaffolds, which include our UniTantrix™ Microcarriers and 3D BioScaffold product lines, are our platform solution for the biomedical industry’s growing needs for high-density cell expansion used in vaccine/viral particle production, cell therapy, tissue engineering, regenerative medicine, and high-throughput/content drug screening, among other applications.


    Our technologies have received patent approvals around the world, including in the United States, Europe, Japan, Taiwan and China, and we continue to conduct extensive R&D in-house as well as with our academic and corporate research  partners.


   At Tantti, our mission is not only to develop innovative biomaterial technologies that provide the highest performing, cost- and time-effective solutions for our customers.  We also aim to become a collaborative partner with our customers, assisting them in realizing their visions of developing innovative biologic products for advanced therapies, whether it is in a small-scale research setting or at the commercial production stage.  We distribute our products around the world, both directly to customers and through our distribution partners.


 Ultimately, we hope our commitment to innovation, quality, and service will drive Tantti’s long-term sustainable growth in the biomaterials industry.  Together with our partners, we strive to become a world-class, global biomaterials company and we sincerely welcome you to collaborate with us, whether as a customer, distributor, research partner, employee or as an investor/shareholder.




Tantti Quality Policy

We are committed to providing our customers with high-quality and innovative products that meet their expectations as well as regulatory requirements.

Tantti Quality Policy

Company History

Company founded
Company headquarters relocated to Taoyuan City, Taiwan
Completion of laboratory facility in Taoyuan City
Signed exclusive licensee agreement with Academia Sinica of Taiwan
Received grant from the Taiwan Innovation and Entrepreneurship Center (TIEC)
Signed joint R&D agreement with NanoMicro, Co,.Ltd.
Participated in 4th International Medical Expo & Conference - Medical Japan 2018
Participated in the American Association for Cancer Research (AACR) Annual Meeting 2018
Completed capital raise with the National Development Fund of Taiwan, Harbinger Venture Management, and China Steel
Received grant from the Taoyuan Small Business Innovation Research (SBIR) program
Signed cooperation agreement with National Health Research Institutes of Taiwan
Participated in the 2018 Taiwan Healthcare Expo
Participated in the 5th International Medical Expo & Conference - Medical Japan
Participated in the 2019 Pittcon Conference & Expo
Completion of second laboratory and production facility in Taoyuan City
Received grant from Taiwan's Ministry of Science and Technology (MOST)
Signed distribution agreement with MBL Beijing Biotech Co., Ltd. (a JSR Life Sciences company) for distribution of Tantti products in China
Participated in the 6th International Medical Expo & Conference - Medical Japan
Selected for and participated in the 3rd Merck Accelerator China program
Renewed distribution agreement with MBL Beijing Biotech Co., Ltd.
Signed innovation project cooperation agreement with Merck KGaA's Innovation Hub (China)
Completed filing of public registration with the Taiwan SEC
Signed distribution agreement with In Vitro Technologies Pty Ltd. (Australia & New Zealand)
Tantti Lab awarded Outstanding Company in Innovation Technology category by 2021 Taipei Biotech Award
ISO 9001:2015 certification
Founders and Advisory Board
Dr. Ging-Ho Hsiue
Chief Scientific Officer
Dr. Hsiue is Tantti's Chief Scientific Officer (CSO) as well as a Professor of Chemical Engineering at National Tsing Hua University (NTHU) in Taiwan.

He was a National Endowed Chair Professor (2006-2009) as well as President of NCHU (2001).

Dr. Hsiue is a recipient of the Lifetime Achievement Award from the Polymer Society of Taiwan (2005) as well as the Scientific Achievement Award from the Japanese Biomaterials Society (2012).

Dr. Juin-Yih Lai
Dr. Lai has been the Professor of Chemical and Materials Engineering at Chung Yuan Christian University (CYCU) in Taiwan since 2006.

At CYCU, he is the founder of the R&D Center for Membrane Technology (2000).

He is also a National Endowed Chair Professor (2014).

Dr. Dyi-Chung Hu
Dr. Hu was the Senior VP of R&D and New Business Development at Unimicron Technology Corp. (TPE:3037) from 2010-2014.

He was also previously the CEO for Chip Power Technology Corp.

Dr. Hu earned his Ph.D. in Material Science and Engineering from the Massachusetts Institute of Technology(MIT).

Dr. Jih-Hsien Lee
Chairman of the Board
Dr. Lee is currently the Chairman of Tantti's Advisory Board.

Prior to Tantti, he was with the Institute for Information Industry and with Datatrans System Inc.

Dr. Lee earned his Ph.D. in Computer Science and Information Engineering from National Central University in Taiwan.

Dr. Hui Chen
Founder & CTO
Dr. Chen is currently Tantti's Chief Technology Officer (CTO).

Prior to Tantti, Dr. Chen was a Professor of Chemical and Materials Engineering at National Central University in Taiwan.

Dr. Chen earned his Ph.D. in Polymer Chemistry from the Tokyo Institute of Technology.

Dr. Pang Lin
Since 2003, Dr. Lin has been a Professor in the Department of Material Science and Engineering at National Chiao Tung University in Taiwan.

Dr. Lin earned his Ph.D. in Material Science and Engineering from the University of California, Los Angeles (UCLA)

Management Team
Joe Yang
President and CEO
For 20+ years has served in senior leadership roles at several biopharma startups and successfully brought a startup to IPO, Sagittarius Life Science Corp. (TPE: 3205).

Investment Manager of Taiwan Biotech Co. Ltd. before founding Tantti Lab.

Frank Liu
Served in senior finance positions in several public and startup companies, including Ford Moto Taiwan, Boehringer Ingelheim Taiwan, Taiwan Biotech Co., Sagittarius Life Science Corp. (brought to IPO) and Concord Medical Co.

Dr. Min Sheu
Ph.D. in Bioengineering; specialized in biomaterials, with 25+ years of product R&D leadership experience in the medical device and biotechnology industries, including Boston Scientific Corp., Covidien (merged with Medtronic), and Sunmax Biotechnology.

Dr. Alan Hu
Director, R&D
Ph.D. in Biochemical Engineering; specialized in bioprocess development, with 15+ years of leadership experience in the wastewater treatment and biotechnology research sectors, including at Imperial College London and National Health Research Institutes, Taiwan.

Yiming Tsai
VP, Production
Served in senior R&D and management positions at several public and startup companies, including Sagittarius Life Science Corp., Taiwan Biotech Co. Ltd. and King to Nin Jiom Medicine Manufactory Co. Ltd.

Specializes in drug development, GMP and ISO.

Steve Wang
Director, Corp. Development
Corporate finance professional with 17+ years of experience advising on mergers and acquisitions, divestitures, and public and private capital raising.

Notable clients included DuPont, Mitsubishi Chemical, Wyeth, Sinopec, among others.

Formerly with Goldman Sachs, Evercore, Credit Suisse and Houlihan Lokey.